IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Login to save this paper or follow this series

Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN

  • Laura Magazzini

    ()

    (Department of Economics, University of Verona)

  • Fabio Pammolli

    ()

    (IMT Lucca Institute for Advanced Studies and CERM Foundation - Competitività, Regole, Mercati)

  • Gianluca Papa

    (Assistant Policy Officer, European Commission)

  • Nicola Carmine Salerno

    ()

    (EIOPA - European Insurance and Occupational Pensions Authority)

Il presente lavoro analizza i principali fatti caratterizzanti i comparti dei farmaci generici puri e dei branded off-patent in Italia, attraverso i dati relativi alle compravendite del 2002 (tramite il SSN e per via privata) di tutti i farmaci a base delle 10 molecole a brevetto scaduto che maggiormente concorrono alla spesa a carico del Servizio Sanitario Nazionale. Il comparto dei branded off-patent comprende, ai fini della presente analisi, sia i branded ex titolari di brevetto (gli originator) che i generici-branded, cioè le loro copie di marca diffuse sul mercato dopo la scadenza del brevetto.

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://www.cermlab.it/wp-content/uploads/cerm/wp/wpcerm-2005-01.pdf
File Function: First version, 2005
Download Restriction: no

Paper provided by Competitività Regole Mecati (CERM) in its series Working Papers with number 01-2005.

as
in new window

Length: 70 pages
Date of creation: Feb 2005
Date of revision:
Handle: RePEc:ern:wpaper:01-2005
Contact details of provider: Postal: Via Fiorentina, 1, 53100 Siena
Phone: +39 3488120691
Web page: http://www.cermlab.it/
Email:


More information through EDIRC

References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:

as in new window
  1. Grabowski, Henry G & Vernon, John M, 1992. "Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act," Journal of Law and Economics, University of Chicago Press, vol. 35(2), pages 331-50, October.
  2. Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo, 2004. "Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure," MPRA Paper 15968, University Library of Munich, Germany.
  3. Hudson, John, 2000. "Generic take-up in the pharmaceutical market following patent expiry: A multi-country study," International Review of Law and Economics, Elsevier, vol. 20(2), pages 205-221, June.
  4. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
  5. Mukesh Eswaran, 1994. "Licensees as Entry Barriers," Canadian Journal of Economics, Canadian Economics Association, vol. 27(3), pages 673-88, August.
  6. Ashiya, Masahiro, 2000. "Weak entrants are welcome," International Journal of Industrial Organization, Elsevier, vol. 18(6), pages 975-984, August.
  7. Yi, Sang-Seung, 1999. "Entry, licensing and research joint ventures," International Journal of Industrial Organization, Elsevier, vol. 17(1), pages 1-24, January.
  8. Hurwitz, Mark A & Caves, Richard E, 1988. "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals," Journal of Law and Economics, University of Chicago Press, vol. 31(2), pages 299-320, October.
  9. Laura Magazzini & Luigi Orsenigo & Fabio Pammolli, 2002. "The intensity of competition after patent expiry in pharmaceuticals. A cross-country analysis," Revue d'Économie Industrielle, Programme National Persée, vol. 99(1), pages 107-131.
  10. Andrew Ching, 2000. "Dynamic Equilibrium in the US Prescription Drug Market After Patent Expiration," Econometric Society World Congress 2000 Contributed Papers 1242, Econometric Society.
Full references (including those not matched with items on IDEAS)

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

When requesting a correction, please mention this item's handle: RePEc:ern:wpaper:01-2005. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: ()

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.

This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.